Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¸¸¼º ½Å»ý¾Æ °£¿°ÀÇ ÀÓ»óÀû °íÂû: ºñ-°¡Á·Çü, ºñ-´ë»ç¼º, ºñ-A, B, CÇü ¹ÙÀÌ·¯½º¼º ½Å»ý¾Æ °£¿° The Clinical Features of Chronic Neonatal Hepatitis: Non-familial, Non-metabolic and Non-A, B, C Viral Hepatitis

´ëÇѼҾƼÒÈ­±â¿µ¾çÇÐȸÁö 2006³â 9±Ç 2È£ p.242 ~ 248
¹ÚÁö¾Ö, ÀÌâÈÆ, ¹ÚÀçÈ«,
¼Ò¼Ó »ó¼¼Á¤º¸
¹ÚÁö¾Ö ( Park Ji-Ae ) 
ºÎ»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç

ÀÌâÈÆ ( Lee Chang-Hun ) 
ºÎ»ê´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
¹ÚÀçÈ« ( Park Jae-Hong ) 
ºÎ»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç

Abstract

¸ñ Àû: ºñ-°¡Á·Çü, ºñ-´ë»ç¼º, ºñ-A, B, CÇü ¹ÙÀÌ·¯½º¼º ½Å»ý¾Æ °£¿°Àº ¾çÈ£ÇÑ °æ°ú¸¦ ÃëÇÑ´Ù°í ¾Ë·ÁÁ® ÀÖÁö¸¸, Àå±âÀûÀÎ °æ°ú °üÂû¿¡ ´ëÇÑ ¿¬±¸°¡ ºÎÁ·ÇÏ´Ù. ¿¬ÀÚµéÀº ÀÌ ÁúȯÀÇ ÀÓ»óÀû Ư¡À» ¿¬±¸ÇÏ¿© ÀÓ»ó °æ°ú ¹× ¿¹ÈÄ ¿¹Ãø¿¡ µµ¿òÀ» ¾ò°íÀÚ ÇÏ¿´´Ù.

¹æ ¹ý: 1998³â 1¿ùºÎÅÍ 2004³â 1¿ù±îÁö »ýÈÄ 3°³¿ù À̳»¿¡ ºÎ»ê´ëÇб³º´¿ø¿¡¼­ ½Å»ý¾Æ °£¿°À¸·Î Áø´ÜµÇ¾ú´ø ȯÀÚ Áß ÀÓ»ó ¼Ò°ß ¹× »ýÈ­ÇÐÀû °Ë»çÀÇ ÀÌ»ó ¼Ò°ßÀÌ 6°³¿ù ÀÌ»ó Áö¼ÓµÇ¾ú´ø 34¸íÀ» ´ë»ó(A, B, CÇü ¹ÙÀÌ·¯½º¼º, ´ë»ç¼º, À¯Àü¼º ½Å»ý¾Æ °£¿°Àº Á¦¿Ü)À¸·Î ÇÏ¿© ÀÓ»óÀû ¼Ò°ß, °Ë»ç½Ç ¼Ò°ß ¹× Á¶Á÷ÇÐÀû ¼Ò°ßÀ» º´·ÂÁö¿Í Á¶Á÷ ½½¶óÀÌµå ºÐ¼®À» ÅëÇØ ÈÄÇâÀûÀ¸·Î ¿¬±¸¸¦ ½ÃÇàÇÏ¿´´Ù.

°á °ú: ¼ººñ´Â 2.4£º1·Î ³²¾Æ°¡ ¸¹¾Ò°í, Áø´Ü ½Ã ¿¬·ÉÀº »ýÈÄ 1¢¦2°³¿ù »çÀÌ°¡ °¡Àå ¸¹¾Ò´Ù. Ç÷û ALTÀÇ ÃÖ°íÄ¡ÀÇ ¹üÀ§´Â ±¤¹üÀ§(100¢¦1,000 IU/L)ÇÏ¿´À¸³ª, 300 IU/L ¹Ì¸¸ÀÌ 41%¿´´Ù. Ç÷û Á÷Á¢Çü ºô¸®·çºóÀÇ ÃÖ°íÄ¡´Â 50%¿¡¼­ 1.0¢¦5.0 mg/dL »çÀÌ¿´´Ù. CMV¿¡ ´ëÇÑ IgM Ç×ü °Ë»ç ¶Ç´Â PCR °Ë»ç¿¡¼­ 34%°¡ ¾ç¼ºÀ̾ú´Ù. ÃßÀû ±â°£ÀÇ Á¶°ÇÀ» ÃæÁ·ÇÑ 29¸í Áß 11¸í(37.9%)ÀÇ È¯ÀÚ°¡ 1³â À̳»¿¡ ALT ¼öÄ¡°¡ Á¤»óÈ­µÇ¾ú°í, 1³â ÀÌ»ó ALT ¼öÄ¡°¡ Áõ°¡µÈ ȯÀÚ 13¸í Áß¿¡¼­´Â 2³â À̳»¿¡ Á¤»óÈ­µÈ °æ¿ì°¡ 9¸í(69.2%), 2³â ÀÌ»ó Áö¼ÓÀûÀ¸·Î »ó½ÂµÈ °æ¿ì°¡ 4¸í(30.7%)¿´´Ù. 2³â ÀÌ»ó Áö¼ÓÀûÀ¸·Î ALT ¼öÄ¡ÀÇ »ó½ÂÀÌ ÀÖ¾ú´ø °æ¿ì °£ Á¶Á÷ °Ë»ç¿¡¼­ °£¹®¸Æ ÁÖº¯ ¼¶À¯È­, °£¹®¸Æ ¿°Áõ ¹× °£¼Ò¿± ¿°Áõ µîÀÇ º¯È­°¡ 2³â À̳»¿¡ ȸº¹µÈ °æ¿ìº¸´Ù ½ÉÇßÀ¸³ª Åë°èÇÐÀûÀÎ Àǹ̴ ¾ø¾ú´Ù.

°á ·Ð: ºñ-°¡Á·Çü, ºñ-´ë»ç¼º, ºñ-A, B, CÇü ¹ÙÀÌ·¯½º¼º ½Å»ý¾Æ °£¿°Àº ºñ±³Àû ¿¹ÈÄ°¡ ¾çÈ£ÇÏÁö¸¸ Ç÷û ALT ¼öÄ¡ÀÇ »ó½ÂÀÌ 1³â ÀÌ»ó Áö¼Ó ½Ã °£ ¼Õ»óÀÇ Á¤µµ¿¡ ´ëÇÑ Æò°¡¿Í ¸¸¼º °£Áúȯ¿¡ ´ëÇÑ ÁÖÀÇ ±íÀº °üÂûÀÌ ÇÊ¿äÇÏ´Ù.

Purpose: Neonatal hepatitis is the major cause of neonatal cholestasis and may be divided into infectious, metabolic, genetic, and idiopathic neonatal hepatitis. Non-familial, non-metabolic, and non-A, B, C viral neonatal hepatitis is known to have made satisfactory progress, but little is known about its chronic clinical features.

Methods: Clinical and histological assessments were carried out in 34 cases with chronic neonatal hepatitis [elevated serum alanine aminotrasferase (ALT) level for more than 6 months] except for A, B, C viral hepatitis, metabolic, or genetic neonatal hepatitis, who were admitted to the Department of Pediatrics, Pusan National University Hospital, from January 1998 to January 2004.

Results: Males were more common (70%). Jaundice (100%) and hepatomegaly (44%) were frequent manifestations. Peak serum ALT levels were most commonly below 300 IU/L in 41.2% of patients and peak serum direct bilirubin levels were most commonly between 1.0¢¦5.0 mg/dL in 50% of patients. Ten cases (34%) of 29 patients had positive serum cytomegalovirus (CMV) IgM or urine CMV polymerase chain reaction. Serum ALT level was normalized within 1 year in 11 (37.9%) of 29 cases, and within 2 years in 9 (69.2%) of 13 cases. Serum ALT level was elevated persistently over 2 years in four (30.7%) of 13 cases. Histologic findings such as portal or periportal activity, lobular necrosis, portal or periportal fibrosis were more severe in patients with persistent ALT elevation over 2 years than in those showing normalization of ALT within 2 years (p£¾0.05).

Conclusion: When the elevation of ALT level sustains over 1 year in non-familiar, non-metabolic, non-A, B, C viral neonatal hepatitis, an assessment of the severity of liver injury and a careful monitoring about chronic liver disease may be required. (Korean J Pediatr Gastroenterol Nutr 2006; 9: 242¢¦248)

Å°¿öµå

Neonatal hepatitis;Chronic;Persistent alanine aminotrasferase elevation

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS